Soleno Therapeutics, Inc. (SLNO)

Market Cap	17.46M
Revenue (ttm)	n/a
Net Income (ttm)	-21.41M
Shares Out	8.16M
EPS (ttm)	-3.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,597
Open	2.00
Previous Close	2.02
Day's Range	1.96 - 2.15
52-Week Range	0.85 - 5.10
Beta	0.17
Analysts	Buy
Price Target	9.18 (+328.97%)
Earnings Date	Mar 30, 2023

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO

Analyst Forecast

According to 8 analysts, the average rating for SLNO stock is "Buy." The 12-month stock price forecast is $9.18, which is an increase of 328.97% from the latest price.

Price Target

$9.18

(328.97% upside)

Analyst Consensus: Buy